Semax
ACTH Neuropeptide Analogue
Heptapeptide analogue of ACTH(4-10) with Met-Glu-His-Phe-Pro-Gly-Pro sequence. Studied for BDNF and NGF upregulation, working memory enhancement, neuroprotection under ischemic conditions, and anxiolytic properties without sedation.
Format
25mg / vial
Purity
>99.3%
Category
Cognitive
Storage
2–8 °C
Research Price
€84
25mg / vial
RESEARCH USE ONLY
This compound is sold exclusively for in-vitro laboratory research. It is not intended for human consumption, therapeutic use, or self-administration. You must be 18+ and a qualified researcher to purchase.
Complete Your Research with the Pen Kit
Precise, painless, repeatable. The clinical-grade injection pen with 32G ultra-fine needles, bacteriostatic water, and your choice of peptide — ready to use out of the box.
€189
View details →Research Protocol Bundles
Cognitive Research Stack
Semax + Selank + Dihexa
Three of the most-studied nootropic peptides from the Russian/Soviet research lineage, plus the potent BDNF-modulating compound Dihexa.
Bundle total
€272
8% bundle saving
Documented Research Parameters
Research Dose
200–600 mcg
Frequency
1–2× daily
Duration
2–8 weeks
Half-Life
~20 minutes (intranasal bioavailability ~75%)
Route(s)
Intranasal · Subcutaneous
Solubility
Water, saline
Reconstitution
Dissolve in sterile 0.9% saline for intranasal use; bacteriostatic water for injectable research.
Key Research Findings
BDNF concentrations in rat prefrontal cortex increase ~2× within 1 hour of intranasal administration.
Anxiolytic effects without sedation or benzodiazepine-like receptor binding — relevant for non-GABAergic anxiolytic research.
Russian-developed neuropeptide with 30+ years of published pharmacological research.
Neuroprotective in models of ischemic stroke — reduces infarct volume and neurological deficit scores.
Administration Reference
Intranasal administration achieves rapid CNS delivery with ~75% bioavailability in animal models. Standard intranasal research approach: head tilted back slightly, administered to each nostril. Subcutaneous injection also documented — abdominal sites typically used. Morning administration aligns with peak cognitive research windows.
Documented Combination Protocols
Cognitive + anxiolytic stack: BDNF upregulation (Semax) combined with GABAergic anxiolysis (Selank).
Synaptogenesis research: complementary pro-cognitive mechanisms via HGF/c-Met and BDNF pathways.
Cognitive + sleep quality research: neuroprotection plus sleep architecture modulation.
IMPORTANT RESEARCH DISCLAIMER
This compound is for in-vitro research and laboratory use only. It has not been evaluated or approved by any regulatory authority for human therapeutic use. It must not be used as a food, drug, or cosmetic. SYNTHEXA assumes no liability for misuse. Handle in accordance with Good Laboratory Practice.